IP Library › Granted Patent US 10,759,721
Granted Patent B2
US 10,759,721 · App. 15/762,264 · Granted Sep 1, 2020

Deuterated CFTR potentiators

Inventors: Adam J. Morgan (Lexington, MA); Roger D. Tung (Lexington, MA)
Assignee: Vertex Pharmaceuticals (Europe) Limited
C07B49/00C07D215/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,759,721
App. No.
15/762,264
Granted
Sep 1, 2020
Kind
B2
Abstract

This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein each X and each R is defined within. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.

Claims (3)

1. A process for the synthesis of compound 28:

comprising converting compound 27:

into compound 28 in the presence of —CD 3 MgI, diethyl ether, and THF.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2018
From: MORGAN, ADAM J.; TUNG, ROGER D.
To: CONCERT PHARMACEUTICALS, INC.
Reel/Frame 046177/0843 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2018
From: CONCERT PHARMACEUTICALS, INC.
To: VERTEX PHARMACEUTICALS (EUROPE) LIMITED
Reel/Frame 046177/0984 →
Continuity (2)
Provisional Application 62232834 · Sep 25, 2015
Related Publication 20200031776A1 · Jan 30, 2020
Cited By (4)
US 12,269,831 US 12,324,802 US 12,421,251 US 12,612,416